Literature DB >> 22677298

Neuroprotective and neurogenesis agent for treating bipolar II disorder: add-on memantine to mood stabilizer works.

Ru-Band Lu, Shiou-Lan Chen, Sheng-Yu Lee, Yun-Hsuan Chang, Shih-Heng Chen, Chun-Hsieh Chu, Nian-Sheng Tzeng, I Hui Lee, Po See Chen, Tzung Lieh Yeh, San-Yuan Huang, Yen Kuang Yang, Jau-Shyong Hong.   

Abstract

Bipolar disorder, characterized by a dysregulation of mood, impulsivity, risky behavior and interpersonal problems, is a recurrent and often becomes chronic psychiatric illness. However, bipolar subtypes are not often recognized in psychiatric settings, especially bipolar II subtype, until Akiskal and Angst made clear definition to bipolar I (BP-I) and bipolar II (BP-II) disorder in 1999. More and more studies, not only on family inheritance, diagnosis, but also on disease process have been reported that BP-I and BP-II are two different disorders with distinct pathological mechanisms. In general, patients with BP-II express less symptoms and have shorter hypomania stages than BP-I. According to a longitudinal research, patients with BP-II have poor recovery than do BP-I patients. Memantine used to be recognized as a noncompetitive N-methyl-d-aspartate receptor antagonist. However, it was found to have neuroprotective and neurogenesis effect in several neurodegenerative diseases in the past years. We found that memantine could inhibit brain inflammatory response through its action on neuroglial cells and provide neurotrophic effect. The above evidences of benefit on auto-immune system with memantine would support that memantine as add-on therapy to valproate might be more effective than valproate alone on improvement of the neuron degeneration in bipolar disorders. Review articles indicate that not only the mood stabilizers provide with good neuroprotection, but the memantine also have conspicuous anti-autoimmune and neurogenesis effect. Therefore, we propose that drugs with neuroprotective effect and neurotrophic effect may treat neurodegenerative diseases including BP-II. The combination treatment of mood stabilizers memantine may not only augment and improve the remedy for bipolar disorders, but also repair the damaged neurons and neurogenesis through activation of astroglial cell and release of neurotrophic factors.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22677298      PMCID: PMC3622707          DOI: 10.1016/j.mehy.2012.04.042

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  58 in total

1.  Treatment guidelines for children and adolescents with bipolar disorder.

Authors:  Robert A Kowatch; Mary Fristad; Boris Birmaher; Karen Dineen Wagner; Robert L Findling; Martha Hellander
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2005-03       Impact factor: 8.829

2.  The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder.

Authors:  Trisha Suppes; Ellen B Dennehy; Robert M A Hirschfeld; Lori L Altshuler; Charles L Bowden; Joseph R Calabrese; M Lynn Crismon; Terence A Ketter; Gary S Sachs; Alan C Swann
Journal:  J Clin Psychiatry       Date:  2005-07       Impact factor: 4.384

3.  Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures: role of microglia.

Authors:  Giia-Sheun Peng; Guorong Li; Nian-Sheng Tzeng; Po-See Chen; De-Maw Chuang; Yaw-Don Hsu; Sufen Yang; Jau-Shyong Hong
Journal:  Brain Res Mol Brain Res       Date:  2004-11-25

4.  Differential features between bipolar I and bipolar II disorder.

Authors:  E Vieta; C Gastó; A Otero; E Nieto; J Vallejo
Journal:  Compr Psychiatry       Date:  1997 Mar-Apr       Impact factor: 3.735

5.  NMDA glutamate but not dopamine antagonists blocks drug-induced reinstatement of morphine place preference.

Authors:  B Ribeiro Do Couto; M A Aguilar; C Manzanedo; M Rodríguez-Arias; J Miñarro
Journal:  Brain Res Bull       Date:  2005-01-30       Impact factor: 4.077

6.  The NMDA antagonist memantine blocks the expression and maintenance of morphine dependence.

Authors:  P Popik; P Skolnick
Journal:  Pharmacol Biochem Behav       Date:  1996-04       Impact factor: 3.533

7.  Atypical antipsychotics in bipolar depression: potential mechanisms of action.

Authors:  Lakshmi N Yatham; Jeffrey M Goldstein; Eduard Vieta; Charles L Bowden; Heinz Grunze; Robert M Post; Trisha Suppes; Joseph R Calabrese
Journal:  J Clin Psychiatry       Date:  2005       Impact factor: 4.384

8.  Transport of brain-derived neurotrophic factor across the blood-brain barrier.

Authors:  W Pan; W A Banks; M B Fasold; J Bluth; A J Kastin
Journal:  Neuropharmacology       Date:  1998-12       Impact factor: 5.250

9.  Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: implications for neurodegenerative diseases.

Authors:  J B Schulz; R T Matthews; D R Henshaw; M F Beal
Journal:  Neuroscience       Date:  1996-04       Impact factor: 3.590

Review 10.  Bipolar depression: phenomenological overview and clinical characteristics.

Authors:  Philip B Mitchell; Gin S Malhi
Journal:  Bipolar Disord       Date:  2004-12       Impact factor: 6.744

View more
  4 in total

1.  A longitudinal study of the association between the GNB3 C825T polymorphism and metabolic disturbance in bipolar II patients treated with valproate.

Authors:  P S Chen; H H Chang; C-C Huang; C C Lee; S-Y Lee; S-L Chen; S-Y Huang; Y K Yang; R-B Lu
Journal:  Pharmacogenomics J       Date:  2016-02-09       Impact factor: 3.550

Review 2.  Memantine: New prospective in bipolar disorder treatment.

Authors:  Giulia Serra; Francesca Demontis; Francesca Serra; Lavinia De Chiara; Andrea Spoto; Paolo Girardi; Giulio Vidotto; Gino Serra
Journal:  World J Psychiatry       Date:  2014-12-22

Review 3.  Intracellular Signaling Cascades in Bipolar Disorder.

Authors:  Gregory H Jones; Carola Rong; Aisha S Shariq; Abhinav Mishra; Rodrigo Machado-Vieira
Journal:  Curr Top Behav Neurosci       Date:  2021

4.  Synaptic and cellular changes induced by the schizophrenia susceptibility gene G72 are rescued by N-acetylcysteine treatment.

Authors:  B Pósfai; C Cserép; P Hegedüs; E Szabadits; D M Otte; A Zimmer; M Watanabe; T F Freund; G Nyiri
Journal:  Transl Psychiatry       Date:  2016-05-10       Impact factor: 6.222

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.